Repligen Corporation (RGEN) — ESG & Values Scores

Environment story

Repligen demonstrates moderate environmental commitment with formal sustainability reporting aligned to GRI, TCFD, and UNGC frameworks. The company discloses participation in sustainability initiatives and has transferred ESG oversight to the Audit Committee in 2025, indicating governance maturity. However, specific Scope 1, 2, and 3 emissions data are not disclosed in the 10-K, precluding quantitative assessment of carbon footprint or decarbonization progress. No net-zero target year is explicitly stated. The company references environmental health & safety policy aiming for 'zero workplace incidents' and sustainability integration into business decisions, but lacks granular emissions metrics, renewable energy percentage, or third-party verified decarbonization infrastructure investments necessary for higher scoring. No significant environmental controversies, fines, or resource depletion issues are disclosed.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

UN Global Compact Membership

Company joined UNGC in support of Ten Principles related to human rights, labor, environment and anti-corruption.

Formal commitment framework; non-binding.
Sustainability Reporting & ESG Strategy

Voluntary annual corporate sustainability reports aligned with GHG Protocol, IFRS Sustainability Alliance (SASB), TCFD and GRI standards. Vice President of Sustainability & ESG appointed to develop and implement strategy.

Transparency and governance maturity; no quantified emissions reduction targets disclosed.
Environmental Health & Safety Policy

Policy advances vision of zero workplace incidents and reduction of environmental impacts.

Aspirational but lacks specific metrics or timelines.
Repligen Performance System (RPS)

Formalized in 2022; continuous improvement framework including sustainability focus. Resulted in productivity savings, lead-time reductions, capacity expansions, quality improvements and manufacturing scrap reductions.

Operational efficiency gains; sustainability component not separately quantified.

Social story

Repligen demonstrates solid social practices with ~2,000 employees as of end-2025, formal Code of Business Conduct & Ethics, and stated commitment to inclusive workforce and fair labor standards. The company provides competitive compensation, benefits globally, and EAP counseling services to all full-time US employees. Collective bargaining coverage is minimal: ~130 employees (6%) in Sweden under two union agreements; ~55 employees (3%) in France under national/local metallurgy collective bargaining. No documented union-suppression activities, strikes, or NLRB complaints disclosed. No CEO-to-worker pay ratio disclosed, limiting Social scoring. Leadership diversity metrics are not quantitatively disclosed; company emphasizes 'inclusive slates' and 'belonging' initiatives but provides no percentage breakdowns for women or underrepresented groups in executive/board positions. Supply-chain labor audits and human rights hazard assessments are not detailed. Employee engagement programs, professional development, and recognition systems are described qualitatively. No major labor controversies or safety incidents disclosed.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Inclusive Workforce & Hiring Practices

Rigorous talent acquisition processes with focus on qualified, inclusive slates of applicants for all roles. Emphasis on hiring diverse candidates and reflecting communities served.

Structural commitment to diversity; no quantified diversity metrics disclosed.
Employee Engagement & Development

Regular engagement surveys, all-hands meetings led by CEO, site town halls, colleague recognition awards, and manager/leadership development programs.

Positive engagement culture; specific retention/turnover data not disclosed.
Health, Safety & Well-Being Programs

All full-time US employees provided EAP with 24/7 counseling and wellness resources. Commitment to employee physical, mental, emotional, social and financial well-being.

Comprehensive employee welfare; specific safety metrics or incident rates not disclosed.
Code of Business Conduct & Ethics

Applied globally; reflects five core principles: trustworthiness, respectfulness, responsibility, fairness, corporate citizenship. All employees and acquisitions integrated into ethics framework.

Formal governance; compliance mechanism in place.

Governance story

Repligen demonstrates strong governance structure with a large-cap profile (market cap ~$6 billion as of June 30, 2025). The company is a Delaware corporation, publicly traded on Nasdaq under RGEN, classified as a 'large accelerated filer' per SEC rules. Board oversight is clearly defined: Audit Committee transferred ESG/sustainability oversight in 2025 to align with regulatory requirements. The company maintains formal quality systems (ISO 9001:2015, ISO 13485:2016 certifications at key sites) and comprehensive intellectual property protection (250+ active US patents, 150+ pending applications). No dual-class share structure, founder supermajority voting issues, or significant antitrust/fraud proceedings are disclosed. Specific board independence percentage is not stated in the 10-K; board composition details deferred to proxy statement (to be filed within 120 days of fiscal year end). Lobbying expenditures are not disclosed in the 10-K. No active litigation, SEC consent decrees, or material fines related to privacy, antitrust, or consumer-protection violations are disclosed. Strong internal control attestation per Sarbanes-Oxley Section 404(b).

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Audit Committee Sustainability Oversight

In 2025, Board transferred sustainability/ESG function oversight to Audit Committee to better align strategies and support increasing sustainability-related regulatory requirements. Committee meets regularly to review strategy, initiatives and reporting.

Enhanced governance alignment and regulatory responsiveness.
Internal Control & Sarbanes-Oxley Compliance

Company filed attestation to management's assessment of internal control effectiveness under SOX Section 404(b); audited by Ernst & Young LLP.

Strong financial controls and audit independence.
Quality Systems & ISO Certifications

Multiple manufacturing sites hold ISO 9001:2015 (quality management) and ISO 13485:2016 (medical device) certifications. Formal quality systems maintain process control, traceability and product conformance.

Operational quality governance; regulatory compliance.
Intellectual Property Protection Framework

Comprehensive IP strategy: 250+ active patent grants, 150+ pending applications; trademark registrations globally; licensing agreements (e.g., 15-year exclusive Daylight Agreement); confidentiality agreements with employees, consultants, partners.

Strong IP governance; competitive moat.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Repligen Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Repligen Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)